Clinical Trial Results: A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Phase 3 trial results for ONS-5010 in neovascular age-related macular degeneration completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Neovascular Age-related Macular Degeneration
• Wet Macular Degeneration

Drugs mentioned

• ONS-5010

Snippet

Sponsor: Outlook Therapeutics, Inc. | Conditions: Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2026-06-30